AIM Research Development from 2010 to 2025

AIM Stock  USD 0.22  0.01  4.35%   
AIM ImmunoTech Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to drop to about 6.9 M. During the period from 2010 to 2025, AIM ImmunoTech Research Development quarterly data regression pattern had sample variance of 7.4 T and median of  6,990,000. View All Fundamentals
 
Research Development  
First Reported
1996-01-31
Previous Quarter
1.1 M
Current Value
1.4 M
Quarterly Volatility
676.8 K
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AIM ImmunoTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AIM ImmunoTech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 203.5 K, Total Revenue of 172.7 K or Gross Profit of 151.2 K, as well as many indicators such as Price To Sales Ratio of 90.46, Dividend Yield of 0.0 or PTB Ratio of 2.28. AIM financial statements analysis is a perfect complement when working with AIM ImmunoTech Valuation or Volatility modules.
  
Check out the analysis of AIM ImmunoTech Correlation against competitors.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.

Latest AIM ImmunoTech's Research Development Growth Pattern

Below is the plot of the Research Development of AIM ImmunoTech over the last few years. It is AIM ImmunoTech's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AIM ImmunoTech's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

AIM Research Development Regression Statistics

Arithmetic Mean7,060,193
Geometric Mean6,491,894
Coefficient Of Variation38.43
Mean Deviation2,082,937
Median6,990,000
Standard Deviation2,713,017
Sample Variance7.4T
Range10.7M
R-Value0.34
Mean Square Error7T
R-Squared0.12
Significance0.19
Slope195,966
Total Sum of Squares110.4T

AIM Research Development History

20256.9 M
202412.6 M
202310.9 M
2022M
20217.7 M
20205.7 M
20194.7 M

About AIM ImmunoTech Financial Statements

AIM ImmunoTech investors utilize fundamental indicators, such as Research Development, to predict how AIM Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development12.6 M6.9 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out the analysis of AIM ImmunoTech Correlation against competitors.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.47)
Revenue Per Share
0.004
Quarterly Revenue Growth
0.19
Return On Assets
(0.80)
Return On Equity
(1.55)
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.